trusted by 100+ Patients

OncoTrace by RGCC

Advanced Cancer Monitoring Through Liquid Biopsy

Treatment Intro

What is OncoTrace?

OncoTrace is a highly advanced liquid biopsy test developed by RGCC, designed to detect and monitor circulating tumor cells (CTCs) in the blood. 

This test provides valuable insights for tracking cancer progression, assessing treatment effectiveness, and detecting potential recurrences - all through a simple blood sample.

Why Choose it

Why Choose OncoTrace?

OncoTrace analyses circulating tumour cells (CTCs) in your bloodstream to detect the presence of cancer and monitor its progression. The test provides a detailed profile of these cells, helping guide treatment decisions and track how the disease responds to therapy over time.
🌿

Non-Invasive and Highly Accurate

Unlike traditional tissue biopsies, OncoTrace requires only a blood sample, offering a safer and more convenient alternative for patients.
🦠

Real-Time Cancer Monitoring

Enables continuous tracking of cancer progression and response to treatment, allowing for timely therapy adjustments.
🛡️

Early Detection of Recurrence

Helps detect cancer recurrence before conventional imaging methods can identify new tumor growth.
🧠

Personalized Treatment Insight

Provides crucial data on the presence and characteristics of circulating tumor cells, aiding in individualised treatment strategies.
⚖️

Powered by RGCC Technology 

Developed by RGCC, a leader in cancer diagnostics and precision medicine.

The process

How Does OncoTrace Work?

OncoTrace is a highly advanced blood test that detects and analyses circulating tumour cells (CTCs) - cancer cells that have detached from a primary tumour and entered the bloodstream. These cells often appear in the early stages of cancer development or during progression and metastasis.

The test uses state-of-the-art molecular and cellular analysis techniques to isolate, identify, and quantify these cells with precision. Each detected CTC is profiled to assess its characteristics, offering insights into tumour biology, aggressiveness, and potential resistance patterns.
Book a consultation

Perfect for

Is This Test Right for You?

Who Can Benefit from OncoTrace?
Patients undergoing cancer treatment who need real-time monitoring
Individuals in remission requiring ongoing surveillance for recurrence
Those at high risk of cancer relapse
Healthcare providers looking for an advanced, non-invasive cancer monitoring tool

FAQs

01

What is the OncoTrace test used for?

OncoTrace is a non-invasive cancer test developed by RGCC that detects and monitors circulating tumor cells (CTCs) in the bloodstream. It is used to track disease progression, evaluate treatment response, and identify early signs of recurrence in patients already diagnosed with cancer.

02

How does OncoTrace support ongoing cancer care?

By analysing CTCs, OncoTrace provides valuable information about a patient’s current cancer status. This helps guide clinical decisions throughout the cancer journey, particularly for patients receiving treatment or those in remission who require ongoing monitoring.

03

Can OncoTrace detect early signs of cancer recurrence?

Yes. The test can help detect changes in cancer behavior and CTC levels that may indicate a potential recurrence, often before it becomes visible on imaging. This makes it useful for timely intervention in high-risk individuals.

04

Who should consider the OncoTrace test?

- Patients currently undergoing cancer treatment

- Individuals in remission needing regular surveillance

- Patients at high risk of disease progression or relapse

- Healthcare providers seeking advanced, non-invasive tools for cancer monitoring

05

Does OncoTrace provide insights into cancer phenotype markers?

The test may include analysis of phenotype markers expressed by CTCs, helping clinicians understand tumour characteristics and refine monitoring or treatment strategies.

06

Is OncoTrace applicable to breast cancer and other types?

Yes, OncoTrace is designed for use across multiple cancer types, including breast cancer. Its utility is based on the presence of detectable CTCs in the bloodstream, which may vary depending on the cancer type and stage.

07

How does OncoTrace differ from traditional cancer screening?

Traditional cancer screening methods focus on detecting cancer in asymptomatic individuals. OncoTrace is used primarily in diagnosed patients for monitoring disease progression and assessing therapy response. It is not intended as a general population screening tool.

08

Can OncoTrace help inform future prognosis?

Yes. Changes in CTC count and characteristics may provide insights into progression and future prognosis, helping clinicians make informed decisions about ongoing care.

09

Can OncoTrace detect circulating tumor cells in all cancer patients?

Yes. OncoTrace is specifically designed to detect circulating tumor cells (CTCs) in the bloodstream. While CTC levels may vary depending on cancer type and stage, the test is applicable to a wide range of cancer patients and provides valuable data for ongoing monitoring.

10

Is OncoTrace useful for patients with multiple primary cancer tumors?

In certain cases, OncoTrace may assist in tracking disease activity in patients diagnosed with multiple primary cancer tumors, as long as the cancers shed detectable cancer cells into the bloodstream. However, the test is best used alongside other clinical assessments to support a comprehensive cancer diagnosis and monitoring plan.